Chapter 49 References Alten R, Doring G, Cutolo M, et al. Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisone. J Rheumatol 2010;37:2025–31. American Academy of Pediatrics. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108:776–89. American College of Rheumatology. Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: an American College of Rheumatology white paper. Arthritis Rheum 2008;59:1058–73. Au K, Reed G, Curtis JR, et al. Extended report: high disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:785–91. Axelsen MB, Eshed I, Horslev-Petersen K, et al. A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial. Ann Rheum Dis 2014 Jan 16. [Epub ahead of print] *Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexatebased, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 2012;156:329–39. Bareille P, Hardes K, Donald AC. Efficacy and safety of once-daily GW870086 a novel selective glucocorticoid in mild-moderate asthmatics: a randomised, two-way crossover, controlled clinical trial. J Asthma 2013;50:1077–82. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet 2009;373:1905–17. Bautmans I, Van De Winkel N, Ackerman A, et al. Recovery of muscular performance after surgical stress in elderly patients. Curr Pharm Des 2014;20:3215–21. Bijlsma JW, Jacobs JW. Glucocorticoid chronotherapy in rheumatoid arthritis. Lancet 2008;371:183–4. Blyth T, Hunter JA, Stirling A. Pain relief in the rheumatoid knee after steroid injection. A singleblind comparison of hydrocortisone succinate, and triamcinolone acetonide or hexacetonide. Br J Rheumatol 1994;33:461–3. Bultink IE, Baden M, Lems WF. Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions. Expert Opin Pharmacother 2013;14:185–97. Burska AN, Roget K, Blits M, et al. Gene expression analysis in RA: towards personalized medicine. Pharmacogenomics J 2014;14:93–106. Buttgereit F, Burmester GR, Straub RH, et al. Exogenous and endogenous glucocorticoids in rheumatic diseases. Arthritis Rheum 2011;63:1–9. *Buttgereit F, da Silva JA, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 2002;61:718–22. 1 EULAR Secretariat | Seestrasse 240 | 8802 Kilchberg | Switzerland T: +41 44 716 30 30 | F: +41 44 716 30 39 M: [email protected] | W: www.eular.org

Buttgereit F, Doering G, Schaeffler A, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 2008a;371:205–14. *Buttgereit F, Straub RH, Wehling M, et al. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 2004;50:3408–17. Buttgereit F, Zhou H, Seibel MJ. Arthritis and endogenous glucocorticoids: the emerging role of the 11beta-HSD enzymes. Ann Rheum Dis 2008b;67:1201–3. Caramaschi P, Biasi D, Dal Forno I, et al. Osteonecrosis in systemic lupus erythematosus: an early, frequent, and not always symptomatic complication. Autoimmune Dis 2012;2012:725249. Chakravarty K, Pharoah PD, Scott DG. A randomized controlled study of post-injection rest following intra-articular steroid therapy for knee synovitis. Br J Rheumatol 1994;33:464–8. Charmandari E, Nicolaides NC, Chrousos GP. Adrenal insufficiency. Lancet 2014;383:2152–67. Chen CY, Tsai CY, Lee PC, et al. Long-term etanercept therapy favors weight gain and ameliorates cachexia in rheumatoid arthritis patients: roles of gut hormones and leptin. Curr Pharm Des 2013;19:1956–64. Chen MJ, Lew HL, Hsu TC, et al. Ultrasound-guided shoulder injections in the treatment of subacromial bursitis. Am J Phys Med Rehabil 2006;85:31–5. Choy EH, Kingsley GH, Khoshaba B, et al. A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs. Ann Rheum Dis 2005;64:1288–93. Compston J, Bowring C, Cooper A, et al. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 2013;75:392–6. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003;348:727–34. Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol 2011;335:2– 13. Criswell LA, Saag KG, Sems KM, et al. Moderate-term, low-dose corticosteroids for rheumatoid arthritis. Cochrane Database Syst Rev 2000:CD001158. Cutolo M, Iaccarino L, Doria A, et al. Efficacy of the switch to modified-release prednisone in rheumatoid arthritis patients treated with standard glucocorticoids. Clin Exp Rheumatol 2013;31:498–505. da Silva JAP, Jacobs JWG, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006;65:285– 93. de Jong PH, Hazes JM, Han HK, et al. Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1year data of the tREACH trial. Ann Rheum Dis 2014;73:1331–9. 2 EULAR Secretariat | Seestrasse 240 | 8802 Kilchberg | Switzerland T: +41 44 716 30 30 | F: +41 44 716 30 39 M: [email protected] | W: www.eular.org

*De Nijs RN, Jacobs JW, Lems WF, et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 2006;355:675–84. *del Rincon I, Battafarano DF, Restrepo JF, et al. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol 2014;66:264–72. den Uyl D, van Raalte DH, Nurmohamed MT, et al. Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction. Arthritis Rheum 2012;64:639–46. den Uyl D, ter Wee M, Boers M, et al. A non-inferiority trial of an attenuated combination strategy ('COBRA-light') compared to the original COBRA strategy: clinical results after 26 weeks. Ann Rheum Dis 2014;73:1071–8. Di Dalmazi G, Pagotto U, Pasquali R, et al. Glucocorticoids and type 2 diabetes: from physiology to pathology. J Nutr Metab 2012;2012:525093. Dixon WG, Abrahamowicz M, Beauchamp ME, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis 2012;71:1128–33. Dixon WG, Kezouh A, Bernatsky S, et al. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. Ann Rheum Dis 2011a;70:956–60. Dixon WG, Suissa S, Hudson M. The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res Ther 2011b;13:R139. Dziurla R, Buttgereit F. Glucocorticoids in rheumatology. Z Rheumatol 2008;67:583–91; quiz 592. Eustace JA, Brophy DP, Gibney RP, et al. Comparison of the accuracy of steroid placement with clinical outcome in patients with shoulder symptoms. Ann Rheum Dis 1997;56:59–63. Gaffney K, Ledingham J, Perry JD. Intra-articular triamcinolone hexacetonide in knee osteoarthritis: factors influencing the clinical response. Ann Rheum Dis 1995;54:379–81. Garcia Rodriguez LA, Hernandez-Diaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res 2001;3:98–101. Garcia-Gomez C, Nolla JM, Valverde J, et al. High HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy. Eur J Clin Invest 2008;38:686–92. Gray RG, Tenenbaum J, Gottlieb NL. Local corticosteroid injection treatment in rheumatic disorders. Semin Arthritis Rheum 1981;10:231–54. Gurwitz JH, Bohn RL, Glynn RJ, et al. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994;154:97–101. Hardy R, Rabbitt EH, Filer A, et al. Local and systemic glucocorticoid metabolism in inflammatory arthritis. Ann Rheum Dis 2008;67:1204–10. Haugeberg G, Strand A, Kvien TK, et al. Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial. Arch Intern Med 3 2005;165:1293–7. EULAR Secretariat | Seestrasse 240 | 8802 Kilchberg | Switzerland T: +41 44 716 30 30 | F: +41 44 716 30 39 M: [email protected] | W: www.eular.org

Hirsch G, Kitas G, Klocke R. Intra-articular corticosteroid injection in osteoarthritis of the knee and hip: factors predicting pain relief–a systematic review. Semin Arthritis Rheum 2013;42:451–73. Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007;66:1560–7. Hoes JN, Jacobs JWG, Buttgereit F, et al. Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nat Rev Rheumatol 2010;6:693–702. Hoes JN, van der Goes MC, van Raalte DH, et al. Glucose tolerance, insulin sensitivity and betacell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. Ann Rheum Dis 2011;70:1887–94. Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 2009;68:1119–24. Jacobs JW, Van Everdingen AA, Verstappen SM, et al. Followup radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo. Arthritis Rheum 2006;54:1422–8. Jacobs JWG, Bijlsma JWJ. Glucocorticoid therapy. In: Firestein CS, Budd RC, Harris ED, et al, eds. Kelley’s textbook of rheumatology, 8th edn. Philadelphia: Saunders Elsevier, 2009: 863–81. Jurgens MS, Jacobs JW, Geenen R, et al. Increase of body mass index in a tight controlled methotrexate-based strategy with prednisone in early rheumatoid arthritis: side effect of the prednisone or better control of disease activity? Arthritis Care Res (Hoboken) 2013;65:88–93. *Kaandorp CJ, Krijnen P, Moens HJ, et al. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum 1997;40:884–92. Kanis JA, Johansson H, Oden A, et al. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 2011;22:809–16. Keenan PA, Jacobson MW, Soleymani RM, et al. The effect on memory of chronic prednisone treatment in patients with systemic disease. Neurology 1996;47:1396–402. Khalife N, Glover V, Taanila A, et al. Prenatal glucocorticoid treatment and later mental health in children and adolescents. PLoS One 2013;8:e81394. *Kirwan JR, Bijlsma JW, Boers M, et al. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007:CD006356. Kleiman A, Tuckermann JP. Glucocorticoid receptor action in beneficial and side effects of steroid therapy: lessons from conditional knockout mice. Mol Cell Endocrinol 2007;275:98–108. Klein BE, Klein R, Lee KE, et al. Drug use and five-year incidence of age-related cataracts: the Beaver Dam Eye Study. Ophthalmology 2001;108:1670–4. Landewé RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347–56. Lim HY, Muller N, Herold MJ, et al. Glucocorticoids exert opposing effects on macrophage function dependent on their concentration. Immunology 2007;122:47–53. 4

EULAR Secretariat | Seestrasse 240 | 8802 Kilchberg | Switzerland T: +41 44 716 30 30 | F: +41 44 716 30 39 M: [email protected] | W: www.eular.org

Lipworth BJ. Therapeutic implications of non-genomic glucocorticoid activity. Lancet 2000;356:87– 9. Listing J, Kekow J, Manger B, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis 2013 Nov 29. [Epub ahead of print] McCarty DJ, Harman JG, Grassanovich JL, et al. Treatment of rheumatoid joint inflammation with intrasynovial triamcinolone hexacetonide. J Rheumatol 1995;22:1631–5. Naranjo A, Sokka T, Descalzo MA, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008;10:R30. Oerlemans R, Vink J, Dijkmans BA, et al. Sulfasalazine sensitises human monocytic/macrophage cells for glucocorticoids by upregulation of glucocorticoid receptor alpha and glucocorticoid induced apoptosis. Ann Rheum Dis 2007;66:1289–95. Ost L, Wettrell G, Bjorkhem I, et al. Prednisolone excretion in human milk. J Pediatr 1985;106:1008–11. Overman RA, Yeh JY, Deal CL. Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res (Hoboken) 2013;65:294–8. Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000;62:385–92. Peltoniemi OM, Kari MA, Lano A, et al. Two-year follow-up of a randomised trial with repeated antenatal betamethasone. Arch Dis Child Fetal Neonatal Ed 2009;94:F402–6. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325–31. Piper JM, Ray WA, Daugherty JR et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991;114:735–40. Ristimaki A, Narko K, Hla T. Down-regulation of cytokine-induced cyclo-oxygenase-2 transcript isoforms by dexamethasone: evidence for post-transcriptional regulation. Biochem J 1996;318:325–31. Ruyssen-Witrand A, Fautrel B, Saraux A, et al. Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine 2011;78:23– 30. Schakman O, Kalista S, Barbe C, et al. Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol 2013;45:2163–72. Schulte HM, Monig H, Benker G, et al. Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. Clin Endocrinol (Oxford) 1987;27:655–62. Seror P, Pluvinage P, d'Andre FL, et al. Frequency of sepsis after local corticosteroid injection (an inquiry on 1160000 injections in rheumatological private practice in France). Rheumatology (Oxford) 1999;38:1272–4. 5 EULAR Secretariat | Seestrasse 240 | 8802 Kilchberg | Switzerland T: +41 44 716 30 30 | F: +41 44 716 30 39 M: [email protected] | W: www.eular.org

Shigemura T, Nakamura J, Kishida S, et al. Incidence of osteonecrosis associated with corticosteroid therapy among different underlying diseases: prospective MRI study. Rheumatology (Oxford) 2011;50:2023–8. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625–39. *Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492–509. Sokka T, Toloza S, Cutolo M, et al. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther 2009;11:R7. Stewart PM, Tomlinson JW. Cortisol, 11 beta-hydroxysteroid dehydrogenase type 1 and central obesity. Trends Endocrinol Metab 2002;13:94–6. Strandberg B. The frequency of myopathy in patients with rheumatoid arthritis treated with triamcinolone. Acta Rheumatol Scand 1962;8:31–4. Svenson KL, Pollare T, Lithell H, et al. Impaired glucose handling in active rheumatoid arthritis: relationship to peripheral insulin resistance. Metabolism 1988;37:125–30. Temprano KK, Bandlamudi R, Moore TL. Antirheumatic drugs in pregnancy and lactation. Semin Arthritis Rheum 2005;35:112–21. Ter Wee MM, den Uyl D, Boers M, et al. Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial. Ann Rheum Dis 2014 May 12. [Epub ahead of print] Tripathi RC, Parapuram SK, Tripathi BJ, et al. Corticosteroids and glaucoma risk. Drugs Aging 1999;15:439–50. Urban RC Jr, Cotlier E. Corticosteroid-induced cataracts. Surv Ophthalmol 1986;31:102–10. van der Goes MC, Jacobs JW, Boers M, et al. Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2010a;69:1015–21. van der Goes MC, Jacobs JWG, Boers M, et al. Monitoring adverse events of low-dose glucocorticoids therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 2010b;69:1913–9. van der Goes MC, Jacobs JW, Jurgens MS, et al. Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied? Osteoporos Int 2013;24:1429– 36. *van Staa TP, Laan RF, Barton IP, et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003;48:3224–9. 6 EULAR Secretariat | Seestrasse 240 | 8802 Kilchberg | Switzerland T: +41 44 716 30 30 | F: +41 44 716 30 39 M: [email protected] | W: www.eular.org

*van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777–87. van Tuyl LH, Plass AM, Lems WF, et al. Discordant perspectives of rheumatologists and patients on COBRA combination therapy in rheumatoid arthritis. Rheumatology (Oxford) 2008;47:1571–6. Vandevyver S, Dejager L, Tuckermann J, et al. New insights into the anti-inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-receptor-mediated transactivation. Endocrinology 2013;154:993–1007. Varis T, Backman JT, Kivisto KT et al. Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone. Clin Pharmacol Ther 2000a;67:215–21. Varis T, Kivisto KT, Backman JT, et al. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. Clin Pharmacol Ther 2000b;68:487–94. Varis T, Kivisto KT, Neuvonen PJ. Grapefruit juice can increase the plasma concentrations of oral methylprednisolone. Eur J Clin Pharmacol 2000c;56:489–93. Wapner RJ, Sorokin Y, Mele L, et al. Long-term outcomes after repeat doses of antenatal corticosteroids. N Engl J Med 2007;357:1190–8. Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc 2006;81:1361–7. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004;141:764–70. Weitoft T, Uddenfeldt P. Importance of synovial fluid aspiration when injecting intra-articular corticosteroids. Ann Rheum Dis 2000;59:233–5. Widdifield J, Bernatsky S, Paterson JM, et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013;65:353–61. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996;71:5–13. Yeh TF, Lin YJ, Lin HC, et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 2004;350:1304–13. Zampeli E, Protogerou A, Stamatelopoulos K, et al. Predictors of new atherosclerotic carotid plaque development in patients with rheumatoid arthritis: a longitudinal study. Arthritis Res Ther 2012;14:R44. Zhao J, Dai YH, Xi QS, et al. A clinical study on insomnia in patients with cancer during chemotherapy containing high-dose glucocorticoids. Pharmazie 2013;68:421–7.

7 EULAR Secretariat | Seestrasse 240 | 8802 Kilchberg | Switzerland T: +41 44 716 30 30 | F: +41 44 716 30 39 M: [email protected] | W: www.eular.org